GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (OTCPK:ATBPF) » Definitions » Cyclically Adjusted PB Ratio

Antibe Therapeutics (Antibe Therapeutics) Cyclically Adjusted PB Ratio : 0.46 (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Antibe Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-04-29), Antibe Therapeutics's current share price is $0.2156. Antibe Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.47. Antibe Therapeutics's Cyclically Adjusted PB Ratio for today is 0.46.

The historical rank and industry rank for Antibe Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

ATBPF' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.84
Current: 0.46

During the past years, Antibe Therapeutics's highest Cyclically Adjusted PB Ratio was 1.84. The lowest was 0.00. And the median was 0.00.

ATBPF's Cyclically Adjusted PB Ratio is ranked better than
75.66% of 641 companies
in the Biotechnology industry
Industry Median: 1.74 vs ATBPF: 0.46

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Antibe Therapeutics's adjusted book value per share data for the three months ended in Dec. 2023 was $0.367. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.47 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Antibe Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Antibe Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Cyclically Adjusted PB Ratio Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.47 0.97

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 0.97 0.73 0.77 1.46

Competitive Comparison of Antibe Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Antibe Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antibe Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Cyclically Adjusted PB Ratio falls into.



Antibe Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Antibe Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.2156/0.47
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibe Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Antibe Therapeutics's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.367/125.4675*125.4675
=0.367

Current CPI (Dec. 2023) = 125.4675.

Antibe Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.855 98.604 1.088
201406 0.727 99.473 0.917
201409 0.431 99.394 0.544
201412 0.221 98.367 0.282
201503 0.072 99.789 0.091
201506 0.187 100.500 0.233
201509 0.071 100.421 0.089
201512 0.490 99.947 0.615
201603 0.382 101.054 0.474
201606 0.429 102.002 0.528
201609 0.339 101.765 0.418
201612 0.349 101.449 0.432
201703 0.235 102.634 0.287
201706 0.272 103.029 0.331
201709 0.240 103.345 0.291
201712 0.157 103.345 0.191
201803 0.311 105.004 0.372
201806 0.284 105.557 0.338
201809 0.229 105.636 0.272
201812 0.193 105.399 0.230
201903 0.229 106.979 0.269
201906 0.165 107.690 0.192
201909 0.250 107.611 0.291
201912 0.187 107.769 0.218
202003 0.092 107.927 0.107
202006 0.589 108.401 0.682
202009 0.444 108.164 0.515
202012 0.340 108.559 0.393
202103 0.875 110.298 0.995
202106 1.137 111.720 1.277
202109 0.988 112.905 1.098
202112 0.922 113.774 1.017
202203 0.862 117.646 0.919
202206 0.780 120.806 0.810
202209 0.672 120.648 0.699
202212 0.607 120.964 0.630
202303 0.558 122.702 0.571
202306 0.498 124.203 0.503
202309 0.417 125.230 0.418
202312 0.367 125.468 0.367

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Antibe Therapeutics  (OTCPK:ATBPF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Antibe Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Antibe Therapeutics (Antibe Therapeutics) Business Description

Traded in Other Exchanges
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.